Nanjing Vazyme Biotech Co Ltd (688105) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Nanjing Vazyme Biotech Co Ltd (688105) has a cash flow conversion efficiency ratio of 0.020x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥75.30 Million ≈ $11.02 Million USD) by net assets (CN¥3.84 Billion ≈ $562.02 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Nanjing Vazyme Biotech Co Ltd (688105) total market value for the company's overall valuation and market capitalisation.
Nanjing Vazyme Biotech Co Ltd - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Nanjing Vazyme Biotech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Nanjing Vazyme Biotech Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nanjing Vazyme Biotech Co Ltd ranked by their cash flow conversion efficiency. Explore earnings quality score of Nanjing Vazyme Biotech Co Ltd to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GIMV NV
BR:GIMB
|
-0.116x |
|
Gestamp Automocion SA
MC:GEST
|
0.122x |
|
EQ Resources Ltd
AU:EQR
|
-0.169x |
|
Northking Information Technology Co
SHE:002987
|
0.027x |
|
Progress Software Corporation
NASDAQ:PRGS
|
0.156x |
|
Grupo Televisa SAB ADR
NYSE:TV
|
0.029x |
|
Pfeiffer Vacuum Technology AG
F:PFV
|
0.099x |
|
Republic Bancorp Inc
NASDAQ:RBCAA
|
0.001x |
Annual Cash Flow Conversion Efficiency for Nanjing Vazyme Biotech Co Ltd (2017–2025)
The table below shows the annual cash flow conversion efficiency of Nanjing Vazyme Biotech Co Ltd from 2017 to 2025. View Nanjing Vazyme Biotech Co Ltd stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥3.79 Billion ≈ $554.78 Million |
CN¥233.16 Million ≈ $34.12 Million |
0.061x | +2605.02% |
| 2024-12-31 | CN¥3.94 Billion ≈ $577.07 Million |
CN¥-9.68 Million ≈ $-1.42 Million |
-0.002x | -104.99% |
| 2023-12-31 | CN¥4.03 Billion ≈ $589.61 Million |
CN¥198.40 Million ≈ $29.03 Million |
0.049x | -69.11% |
| 2022-12-31 | CN¥4.61 Billion ≈ $674.90 Million |
CN¥735.17 Million ≈ $107.58 Million |
0.159x | +6.66% |
| 2021-12-31 | CN¥4.13 Billion ≈ $603.95 Million |
CN¥616.80 Million ≈ $90.26 Million |
0.149x | -75.22% |
| 2020-12-31 | CN¥1.33 Billion ≈ $194.97 Million |
CN¥803.55 Million ≈ $117.59 Million |
0.603x | +693.51% |
| 2019-12-31 | CN¥200.02 Million ≈ $29.27 Million |
CN¥15.20 Million ≈ $2.22 Million |
0.076x | +415.63% |
| 2018-12-31 | CN¥166.08 Million ≈ $24.30 Million |
CN¥-4.00 Million ≈ $-585.21K |
-0.024x | +5.92% |
| 2017-12-31 | CN¥150.82 Million ≈ $22.07 Million |
CN¥-3.86 Million ≈ $-564.87K |
-0.026x | -- |
About Nanjing Vazyme Biotech Co Ltd
Nanjing Vazyme Biotech Co., Ltd offers technology solutions for life science, biomedicine, and in vitro diagnostics. The company offers nucleic acid extraction reagents, including DNA extraction, RNA extraction, microbiome nucleic acid extraction, sample treatment, and high-throughput automated extraction; molecular biology reagents comprising PCR, cloning/mutagenesis, reverse transcription, real… Read more